SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01
— SpyBiotech’s lead program is targeting human cytomegalovirus (HCMV) — Oxford, UK and Cambridge, MA (December 7, 2023) — SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, today announced that the first subject has been dosed with SPYVLP01, a candidate vaccine targeting human cytomegalovirus […]
SpyBiotech Announces First Patient Dosed in Phase I Trial of SPYVLP01 Read More »